Genedata Biologics Licensed by Pfizer Inc.

Basel, Switzerland, March 3, 2015

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Pfizer Inc. has licensed the Genedata BiologicsTM enterprise platform for use at Pfizer biopharma research and development sites in the US and Europe. Genedata is supporting Pfizer’s global deployment and roll out project at Pfizer’s Global Biotherapeutic Technologies (GBT), Centers for Therapeutic Innovation (CTI), and Pharmaceutical Sciences groups.

“Pfizer is pleased to gain full access to this system for antibody discovery and protein engineering, which we hope will become part of Pfizer’s large-molecule discovery engine,” said Dr. Will Somers, VP of Global Biotherapeutic Technologies at Pfizer.

Genedata Biologics helps increase biopharma research efficiency by integrating, in one single system, diverse antibody discovery workflows, and streamlining all molecular biology, expression, purification, and analytics processes,” said Dr. Othmar Pfannes, CEO of Genedata. “The platform flexibly addresses proprietary workflows and technologies as well as new requirements such as next-generation antibody formats and novel library technologies. All mission-critical data on therapeutic candidates such as bioactivity, developability, and manufacturability can be managed by Genedata Biologics, which enables transparent decision-making on candidates to move forward with.”

“One of the reasons we chose Genedata Biologics was the platform’s process coverage. We required that the full diversity of Pfizer’s large-molecule processes and technologies be supported by one integrated system,” said Dr. Sergio Rotstein, Director of Research Business Technology at Pfizer. “Genedata Biologics’ flexibility allows Pfizer to configure the system to address both proprietary discovery processes as well as Pfizer-specific business processes and nomenclature.”

“We are delighted to have Pfizer choose Genedata Biologics, another validation that our platform is increasingly recognized as the premier biologics R&D workflow system,” continued Dr. Pfannes. “Our partners are looking at our system to make their lead discovery and development process more efficient. Genedata Biologics enables true high throughputs in generating and validating candidates and we will continue to invest into Genedata Biologics to meet the rapidly growing demands in this exciting field.”
 
In the four short years since its release in 2011, Genedata Biologics has been rapidly adopted by more than a third of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations and technology transfer, to large, global, multi-site partnerships.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
www.genedata.com
Follow Us on LinkedIn

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.